Walter-Sack I, Gresser U, Adjan M, Kamilli I, Ittensohn A, de Vries J X, Weber E, Zöllner N
Abteilung Klinische Pharmakologie, Medizinischen Klinik, Universität Heidelberg, FRG.
Eur J Clin Pharmacol. 1990;39(2):173-6. doi: 10.1007/BF00280054.
The plasma benzbromarone concentration-time profile in a healthy subject who retained the compound much longer than other individuals is described. The data suggested that determination of the 24 h plasma concentration of the parent drug after a single oral dose of 100 mg benzbromarone would be an appropriate procedure to determine the elimination phenotype. Based on this procedure, 148 of 153 healthy individuals (97%) in a population study were found to eliminate benzbromarone rapidly. In one subject the 24 h benzbromarone plasma concentration was very similar to that observed in the individual who had been more fully characterized. Four participants gave intermediate results. The data are compatible with a bimodal or trimodal distribution of different benzbromarone elimination phenotypes.
描述了一名健康受试者体内苯溴马隆的血浆浓度-时间曲线,该受试者对该化合物的保留时间比其他个体长得多。数据表明,单次口服100 mg苯溴马隆后测定母体药物的24小时血浆浓度将是确定消除表型的合适方法。基于此方法,在一项群体研究中,153名健康个体中有148名(97%)被发现能快速消除苯溴马隆。在一名受试者中,24小时苯溴马隆血浆浓度与在已得到更全面表征的个体中观察到的浓度非常相似。四名参与者给出了中间结果。这些数据与不同苯溴马隆消除表型的双峰或三峰分布相符。